ProShares UltraShort Bloomberg Natural Gas ETF vs Tempus AI — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.69 (market cap $141.25M), while Tempus AI trades at $71.21 (market cap $12.58B). The key difference: Tempus AI is far larger — about 89.1× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and Tempus AI is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days and Tempus AI for 23 Days on average.
| KOLD | TEM | |
|---|---|---|
Market Cap | $141.25M | $12.58B |
Volume | 5,492,367 | 7,444,569 |
Sector | Leveraged / Inverse | Broad Market / Factor |
52-Week High | $49.39 | $99.28 |
52-Week Low | $13.58 | $41.55 |
Typical Hold Time | 10 Days | 23 Days |
Enterprise Value | — | $13.21B |
Signals from Pluang's Aura AI — not financial advice
KOLD is trading at $24.475, down 1.47% on the day, with a bearish technical outlook as moving averages signal strong selling pressure. The stock faces headwinds from record-high natural gas production and mild weather forecasts that are weighing on energy sector sentiment. Recent news highlights geopolitical tensions in the Middle East and supply dynamics affecting natural gas markets, creating volatility for energy-related investments.
The outlook remains cautious given the bearish technical indicators and fundamental pressures from oversupply conditions in natural gas markets. Investment opportunities exist for contrarian investors betting on geopolitical risk premiums, but risks include continued production growth and weather-dependent demand uncertainty that could pressure energy sector performance in the near term.
Tempus AI (TEM) trades at $71.46, up 1.66% with a bullish technical signal despite negative profitability metrics. The stock shows strong analyst support with 9 buy ratings and a $72.60 consensus target. Recent FDA clearance for ECG-MR AI product and 13 ESMO Congress presentations highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist at -$254M.
Outlook remains cautiously optimistic given strong institutional backing and AI healthcare growth potential, but profitability challenges and insider selling present near-term risks. The stock's valuation appears stretched with P/S of 8.61 and P/B of 28.27, requiring sustained revenue acceleration to justify current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →